4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Atrium Therapeutics, Inc. (RNA) operates in the Biotechnology industry and is headquartered in San Diego, United States. Its market capitalization is roughly $141 million. In the fiscal year ended 2025-12-31, RNA reported $19M in revenue and ($77M) in net income.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies.
Interactive charts & full statements → Open the RNA valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Revenue | $36M | $19M | $11M | $10M |
| Operating Income (EBIT) | ($96M) | ($77M) | ($13M) | ($6M) |
| Net Income | ($93M) | ($77M) | ($25M) | ($6M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $3M | $20M | $1M | $12M | $4M | — |
| Operating Income (EBIT) | ($23M) | ($17M) | ($48M) | ($8M) | ($13M) | — |
| Net Income | ($20M) | ($17M) | ($48M) | ($8M) | ($13M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets | $278M | $7M | $10M |
| Total Liabilities | $71M | $68M | $81M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RNA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms